A PHASE 2, SINGLE-ARM, MULTICOHORT, OPEN LABEL, MULTICENTER TRIAL OF OFF-THE-SHELF NATURAL KILLER (NK) CELLS (SAR445419) IN PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

Registry ID

ACT17550

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

SANOFI-AVENTIS CANADA INC

Last update

2023-02-20

Conditions

• MYELOID MALIGNANCIES

View on source registry